Table 3.
Multivariate analysis of the association between clinical characteristics and survival in all patients and landmark group patients diagnosed with advanced gastric cancer
| All patients | Landmark patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | |||||||||
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| ECOG PS | ||||||||||||
| 0–1 | 1 | 1 | 1 | 1 | ||||||||
| 2 | 1.178 | 0.854–1.624 | 0.317 | 1.474 | 1.067–2.036 | 0.019 | 1.167 | 0.813–1.674 | 0.402 | 1.470 | 1.022–2.113 | 0.038 |
| Baseline platelet counts, × 109/L | 1.002 | 1.000–1.003 | 0.021 | |||||||||
| Differentiation | ||||||||||||
| Well‐moderate | 1 | 1 | 1 | 1 | ||||||||
| Poor | 1.418 | 1.091–1.842 | 0.009 | 1.700 | 1.307–2.213 | <0.001 | 1.332 | 1.006–1.764 | 0.045 | 1.675 | 1.264–2.221 | <0.001 |
| Number of metastatic sites | ||||||||||||
| ≤2 | 1 | 1 | 1 | 1 | ||||||||
| >2 | 1.648 | 1.243–2.185 | 0.001 | 1.392 | 1.053–1.841 | 0.020 | 1.762 | 1.281–2.422 | <0.001 | 1.478 | 1.081–2.022 | 0.014 |
| Timing of CIN | ||||||||||||
| Non‐early‐onset | 1 | 1 | 1 | 1 | ||||||||
| Early‐onset | 0.574 | 0.453–0.729 | <0.001 | 0.607 | 0.478–0.770 | <0.001 | 0.584 | 0.450–0.758 | <0.001 | 0.619 | 0.477–0.803 | <0.001 |
CI, confidence interval; HR, hazard ratio; PFS, progression‐free survival; OS, overall survival.
Statistical significance was defined as a two‐sided P < 0.05.
Hazard ratios and 95% CIs for OS and PFS were estimated with Cox's proportional hazards models.
Adjusted for gender; age; ECOG PS; baseline hemoglobin concentration; baseline neutrophil, lymphocyte, and platelet counts; differentiation; liver and peritoneal metastases; number of metastatic sites; and timing of CIN.